AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management pipeline, including AZD5004 and AZD6234, shows significant growth potential, especially with strategic hires and advancements in clinical trials. Financial performance in Q3 2024 was robust, with a ...
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.
AstraZeneca PLC (NASDAQ:AZN ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - Executive Vice President, Oncology Business Susan Galbraith - Executive Vice President, Oncology Research and Development Ruud Dobber - Ex...
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.
AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China. The post AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat appeared first on Investor's Business Daily.
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with the government over incentives continue.
AstraZeneca PLC (LSE:AZN) chief executive Pascal Soriot has signalled the company is taking a criminal probe into its Chinese business “very seriously”. Soriot on Tuesday said AstraZeneca would “fully cooperate” with Chinese authorities over the case, which has seen China president Leon Wang detained.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.